Diabetic neuropathy: what's in the pipeline?
Diabetic neuropathy is a common complication of both type 1 and type 2 diabetes. Treatment options are available to mitigate the symptoms associated with the two major types of diabetic neuropathy, namely peripheral and autonomic neuropathy. However, there is a lack of therapeutic options to prevent, treat and reverse the underlying pathogenesis of diabetic neuropathy. Several therapies including benfotiamine, alpha-lipoic acid, protein kinase C inhibitors, aldose-reductase inhibitors, nerve growth factors and Actovegin have shown potential --but not proven-- benefits for peripheral neuropathy. Nonetheless, three clinical phase II trials are currently underway to evaluate three therapeutic agents for diabetic peripheral neuropathy. Unfortunately, there are less promising therapeutic options in development for autonomic neuropathy management. Despite the fact that many agents have been evaluated for treating autonomic neuropathy, including anti-advanced glycation end products (angiotensin-converting enzyme inhibitors, benfotiamine, aminoguanidine), bromocriptine-QR and alpha-lipoic acid, studies have shown minimal efficacy or outcomes are pending..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:043 |
|---|---|
| Enthalten in: |
Drugs of the future - 043(2018), 5, Seite 0339 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Akiyode,US!aO. [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1358/dof.2018.043.05.2807862 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2000500153 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2000500153 | ||
| 003 | DE-627 | ||
| 005 | 20230516073303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180809s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dof.2018.043.05.2807862 |2 doi | |
| 028 | 5 | 2 | |a fidpha__2018-08-09.pp |
| 035 | |a (DE-627)OLC2000500153 | ||
| 035 | |a (DE-599)GBVOLC2000500153 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Akiyode,US!aO. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diabetic neuropathy: what's in the pipeline? |
| 264 | 1 | |c 2018 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Diabetic neuropathy is a common complication of both type 1 and type 2 diabetes. Treatment options are available to mitigate the symptoms associated with the two major types of diabetic neuropathy, namely peripheral and autonomic neuropathy. However, there is a lack of therapeutic options to prevent, treat and reverse the underlying pathogenesis of diabetic neuropathy. Several therapies including benfotiamine, alpha-lipoic acid, protein kinase C inhibitors, aldose-reductase inhibitors, nerve growth factors and Actovegin have shown potential --but not proven-- benefits for peripheral neuropathy. Nonetheless, three clinical phase II trials are currently underway to evaluate three therapeutic agents for diabetic peripheral neuropathy. Unfortunately, there are less promising therapeutic options in development for autonomic neuropathy management. Despite the fact that many agents have been evaluated for treating autonomic neuropathy, including anti-advanced glycation end products (angiotensin-converting enzyme inhibitors, benfotiamine, aminoguanidine), bromocriptine-QR and alpha-lipoic acid, studies have shown minimal efficacy or outcomes are pending. | ||
| 700 | 1 | |a Lajthia,US!aE. |e verfasserin |4 aut | |
| 700 | 1 | |a Unonu,US!aJ. |e verfasserin |4 aut | |
| 700 | 1 | |a Ketema,US!aP. |e verfasserin |4 aut | |
| 700 | 1 | |a Olagundoye,US!aY. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of the future |d Barcelona : Prous Science - Thomson Reuters, 1976 |g 043(2018), 5, Seite 0339 |w (DE-627)13048489X |w (DE-600)752959-4 |w (DE-576)016071395 |x 0377-8282 |7 nnns |
| 773 | 1 | 8 | |g volume:043 |g year:2018 |g number:5 |g pages:0339 |
| 856 | 4 | 0 | |u https://doi.org/10.1358/dof.2018.043.05.2807862 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_4125 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 043 |j 2018 |e 5 |h 0339 | ||